The stock of Verve Therapeutics Inc (VERV) has gone down by -2.37% for the week, with a -50.00% drop in the past month and a -42.58% drop in the past quarter. The volatility ratio for the week is 6.93%, and the volatility levels for the past 30 days are 7.44% for VERV. The simple moving average for the past 20 days is -24.97% for VERV’s stock, with a -50.62% simple moving average for the past 200 days.
Is It Worth Investing in Verve Therapeutics Inc (NASDAQ: VERV) Right Now?
Additionally, the 36-month beta value for VERV is 1.88. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for VERV is 54.79M and currently, short sellers hold a 28.03% ratio of that float. The average trading volume of VERV on April 25, 2024 was 1.29M shares.
VERV) stock’s latest price update
Verve Therapeutics Inc (NASDAQ: VERV)’s stock price has dropped by -4.36 in relation to previous closing price of 6.88. Nevertheless, the company has seen a loss of -2.37% in its stock price over the last five trading days. The Motley Fool reported 2024-04-06 that Verve Therapeutics just had a major mishap in a clinical trial. However, it has a backup plan that’s already in action.
Analysts’ Opinion of VERV
Many brokerage firms have already submitted their reports for VERV stocks, with H.C. Wainwright repeating the rating for VERV by listing it as a “Buy.” The predicted price for VERV in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on April 08, 2024 of the current year 2024.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see VERV reach a price target of $29. The rating they have provided for VERV stocks is “Buy” according to the report published on April 13th, 2023.
Cantor Fitzgerald gave a rating of “Neutral” to VERV, setting the target price at $21 in the report published on February 01st of the previous year.
VERV Trading at -45.30% from the 50-Day Moving Average
After a stumble in the market that brought VERV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.28% of loss for the given period.
Volatility was left at 7.44%, however, over the last 30 days, the volatility rate increased by 6.93%, as shares sank -48.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -51.01% lower at present.
During the last 5 trading sessions, VERV fell by -2.37%, which changed the moving average for the period of 200-days by -66.88% in comparison to the 20-day moving average, which settled at $8.46. In addition, Verve Therapeutics Inc saw -52.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VERV starting from Nickerson Joan, who sale 1,514 shares at the price of $8.24 back on Apr 02 ’24. After this action, Nickerson Joan now owns 8,659 shares of Verve Therapeutics Inc, valued at $12,475 using the latest closing price.
Dorval Allison, the Chief Financial Officer of Verve Therapeutics Inc, sale 554 shares at $11.45 during a trade that took place back on Nov 29 ’23, which means that Dorval Allison is holding 4,060 shares at $6,343 based on the most recent closing price.
Stock Fundamentals for VERV
Current profitability levels for the company are sitting at:
- -18.98 for the present operating margin
- 0.11 for the gross margin
The net margin for Verve Therapeutics Inc stands at -16.48. The total capital return value is set at -0.31. Equity return is now at value -34.78, with -27.94 for asset returns.
Based on Verve Therapeutics Inc (VERV), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.0. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is 35.51.
Currently, EBITDA for the company is -217.67 million with net debt to EBITDA at 0.6. When we switch over and look at the enterprise to sales, we see a ratio of 32.79. The receivables turnover for the company is 1.99for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.24.
Conclusion
In conclusion, Verve Therapeutics Inc (VERV) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
